Literature DB >> 21243355

One should not just read what one believes: the nearly irresolvable issue of producing truly objective, evidence-based guidelines for the management of differentiated thyroid cancer.

Markus Dietlein, F A Verburg, M Luster, C Reiners, F Pitoia, H Schicha.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21243355     DOI： 10.1007/s00259-011-1728-x

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  32 in total

1.  Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  F Pacini; M G Castagna; L Brilli; G Pentheroudakis
Journal:  Ann Oncol       Date:  2010-05       Impact factor: 32.976

2.  [Procedure guideline for iodine-131 whole-body scintigraphy for differentiated thyroid cancer (version 3)].

Authors:  M Dietlein; J Dressler; W Eschner; F Grünwald; M Lassmann; B Leisner; M Luster; C Reiners; H Schicha; O Schober
Journal:  Nuklearmedizin       Date:  2007       Impact factor: 1.379

3.  Prospective randomized clinical trial to evaluate the optimal dose of 131 I for remnant ablation in patients with differentiated thyroid carcinoma.

Authors:  C Bal; A K Padhy; S Jana; G S Pant; A K Basu
Journal:  Cancer       Date:  1996-06-15       Impact factor: 6.860

4.  Diagnostic 131-iodine whole-body scan may be avoided in thyroid cancer patients who have undetectable stimulated serum Tg levels after initial treatment.

Authors:  F Pacini; M Capezzone; R Elisei; C Ceccarelli; D Taddei; A Pinchera
Journal:  J Clin Endocrinol Metab       Date:  2002-04       Impact factor: 5.958

5.  Low-activity (2.0 GBq; 54 mCi) radioiodine post-surgical remnant ablation in thyroid cancer: comparison between hormone withdrawal and use of rhTSH in low-risk patients.

Authors:  M Chianelli; V Todino; F M Graziano; C Panunzi; D Pace; R Guglielmi; A Signore; E Papini
Journal:  Eur J Endocrinol       Date:  2008-12-12       Impact factor: 6.664

6.  Radioiodine dose for remnant ablation in differentiated thyroid carcinoma: a randomized clinical trial in 509 patients.

Authors:  C S Bal; Ajay Kumar; G S Pant
Journal:  J Clin Endocrinol Metab       Date:  2004-04       Impact factor: 5.958

7.  Guidelines for radioiodine therapy of differentiated thyroid cancer.

Authors:  M Luster; S E Clarke; M Dietlein; M Lassmann; P Lind; W J G Oyen; J Tennvall; E Bombardieri
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-10       Impact factor: 9.236

Review 8.  Follow-up of low-risk patients with differentiated thyroid carcinoma: a European perspective.

Authors:  Martin Schlumberger; Gertrud Berg; Ohad Cohen; Leonidas Duntas; François Jamar; Barbara Jarzab; Eduard Limbert; Peter Lind; Furio Pacini; Christoph Reiners; Franco Sánchez Franco; Anthony Toft; Wilmar M Wiersinga
Journal:  Eur J Endocrinol       Date:  2004-02       Impact factor: 6.664

9.  [Procedure guidelines for radioiodine therapy of differentiated thyroid cancer (version 3)].

Authors:  M Dietlein; J Dressler; W Eschner; F Grünwald; M Lassmann; B Leisner; M Luster; E Moser; Chr Reiners; H Schicha; O Schober
Journal:  Nuklearmedizin       Date:  2007       Impact factor: 1.379

10.  A comparison of 1850 (50 mCi) and 3700 MBq (100 mCi) 131-iodine administered doses for recombinant thyrotropin-stimulated postoperative thyroid remnant ablation in differentiated thyroid cancer.

Authors:  Tania Pilli; Ernesto Brianzoni; Francesca Capoccetti; Maria Grazia Castagna; Sara Fattori; Angela Poggiu; Gloria Rossi; Francesca Ferretti; Elisa Guarino; Luca Burroni; Angelo Vattimo; Claudia Cipri; Furio Pacini
Journal:  J Clin Endocrinol Metab       Date:  2007-07-03       Impact factor: 5.958
View more
  2 in total

Review 1.  The Treatment of Well-Differentiated Thyroid Carcinoma.

Authors:  Ralf Paschke; Thomas Lincke; Stefan P Müller; Michael C Kreissl; Henning Dralle; Martin Fassnacht
Journal:  Dtsch Arztebl Int       Date:  2015-06-26       Impact factor: 5.594

2.  Difficulties in deciding whether to ablate patients with putatively "low-intermediate-risk" differentiated thyroid carcinoma: do guidelines mainly apply in the centres that produce them? Results of a retrospective, two-centre quality assurance study.

Authors:  Savvas Frangos; Ioannis P Iakovou; Robert J Marlowe; Nicolaos Eftychiou; Loukia Patsali; Anna Vanezi; Androulla Savva; Vassilis Mpalaris; Evanthia I Giannoula
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-08-01       Impact factor: 9.236
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.